Skip to main content
Clinical Trials/PACTR202305669258195
PACTR202305669258195CompletedPhase 2

Impact of the association of Tadalafil and Silodosin on the recurrence of acute urinary retention secondary to benign prostate hyperplasia:Randomized double-blind clinical trial

oghmari Ahmed0 sites48 target enrollmentStarted: April 27, 2023Last updated:

Trial Snapshot

Phase
Phase 2
Status
Completed
Sponsor
Enrollment
48

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
45 Year(s) to 64 Year(s) (—)
Sex
Male

Inclusion Criteria

  • The study enrolled consenting male patients
  • Aged more than 45 years
  • Presenting acute urinary retention (AUR) (first episode) secondary to benign prostatic hyperplasia (BPH)
  • Not presenting personal history of AUR, prostate cancer, prostatectomy, tumorous duct obstruction, lower urinary tract infection, lower urinary tract surgery, AUR after surgery
  • With no simultaneous use of drugs having interactions with Tadalafil or Silodosine

Exclusion Criteria

  • Patients who did not complete the follow-up
  • Patients in whom a significant prostatic protrusion index was discovered during the study
  • Patients in whom a bladder lithiasis, or bladder diverticulum were discovered

Investigators

Sponsor
oghmari Ahmed

Similar Trials